Short Interest in Pharvaris N.V. (NASDAQ:PHVS) Decreases By 42.9%

Pharvaris N.V. (NASDAQ:PHVS) was the target of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totaling 600,645 shares, a decrease of 42.9% from the April 30th total of 1,051,478 shares. Based on an average daily volume of 463,899 shares, the short-interest ratio is presently 1.3 days. Currently, 1.0% of the shares of the company are sold short.

Insider Buying and Selling at Pharvaris

In other news, insider Peng Lu sold 15,000 shares of the company’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.24, for a total transaction of $453,600.00. Following the transaction, the insider owned 66,083 shares of the company’s stock, valued at $1,998,349.92. This represents a 18.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anne Lesage sold 21,700 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.26, for a total value of $656,642.00. Following the transaction, the insider owned 56,450 shares of the company’s stock, valued at $1,708,177. The trade was a 27.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 209,948 shares of company stock valued at $6,268,141 in the last quarter. Insiders own 11.84% of the company’s stock.

Hedge Funds Weigh In On Pharvaris

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new position in Pharvaris in the 4th quarter worth about $35,000. Barclays PLC purchased a new position in shares of Pharvaris during the fourth quarter worth about $77,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Pharvaris during the third quarter worth about $75,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Pharvaris in the fourth quarter worth approximately $86,000. Finally, JPMorgan Chase & Co. raised its stake in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter.

Pharvaris Trading Down 0.3%

Shares of PHVS stock traded down $0.08 during trading hours on Tuesday, reaching $29.02. The stock had a trading volume of 143,389 shares, compared to its average volume of 357,013. The stock’s fifty day simple moving average is $28.86 and its 200 day simple moving average is $27.16. The firm has a market capitalization of $1.90 billion, a PE ratio of -9.06 and a beta of -2.35. Pharvaris has a 12 month low of $15.91 and a 12 month high of $33.33.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. As a group, equities research analysts anticipate that Pharvaris will post -3.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on PHVS shares. Wall Street Zen raised shares of Pharvaris from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Citizens Jmp lowered their price target on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 13th. Wedbush upped their price target on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Royal Bank Of Canada cut their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Finally, UBS Group set a $74.00 target price on shares of Pharvaris in a report on Wednesday, May 13th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $49.18.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.